ImmunotherapyVol. 4, No. 5 EditorialBispecific antibodies and diabodies for cancer immunotherapyUrsula Elsässer-Beile & Patrick BühlerUrsula Elsässer-Beile* Author for correspondenceExperimental Urology, Department of Urology, University Medical Centre Freiburg, Germany. Search for more papers by this authorEmail the corresponding author at ursula.elsaesser@uniklinik-freiburg.de & Patrick BühlerExperimental Urology, Department of Urology, University Medical Centre Freiburg, GermanySearch for more papers by this authorPublished Online:29 May 2012https://doi.org/10.2217/imt.12.18AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View article"Bispecific antibodies and diabodies for cancer immunotherapy." , 4(5), pp. 459–460Keywords: bispecific moleculesdiabodiesimmunotherapyT-cell-mediated lysisT-cell retargetingReferences1 Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur. J. Immunol.33(5),1334–1340 (2003).Crossref, Medline, CAS, Google Scholar2 Müller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs24(2),89–98 (2010).Crossref, Medline, CAS, Google Scholar3 Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr. Opin Mol. Ther.11(1),22–30 (2009).Medline, CAS, Google Scholar4 Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Curr. Opin Immunol.11(5),558–562 (1999).Crossref, Medline, CAS, Google Scholar5 Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol.23(9),1126–1136 (2005).Crossref, Medline, CAS, Google Scholar6 Kipriyanov SM, Moldenhauer G, Schuhmacher J et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol.293(1),41–56 (1999).Crossref, Medline, CAS, Google Scholar7 Kontermann RE. Alternative antibody formats. Curr. Opin. Mol. Ther.12(2),176–183.Medline, Google Scholar8 Grosse-Hovest L, Muller S, Minoia R et al. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc. Natl Acad. Sci. USA101(18),6858–6863 (2004).Crossref, Medline, CAS, Google Scholar9 Bakker JM, Bleeker WK, Parren PW. Therapeutic antibody gene transfer: an active approach to passive immunity. Mol. Ther.10(3),411–416 (2004).Crossref, Medline, CAS, Google Scholar10 Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science321(5891),974–977 (2008).Crossref, Medline, CAS, Google Scholar11 Topp MS, Kufer P, Gokbuget N et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol.29(18),2493–2498 (2011).Crossref, Medline, CAS, Google Scholar12 Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev.36(6),458–467 (2010).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 4, No. 5 Follow us on social media for the latest updates Metrics Downloaded 610 times History Published online 29 May 2012 Published in print May 2012 Information© Future Medicine LtdKeywordsbispecific moleculesdiabodiesimmunotherapyT-cell-mediated lysisT-cell retargetingFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download